PFS Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$384K Buy
321
+1
+0.3% +$1.02K 0.16% 63
2026
Q1
$295K Hold
320
0.14% 66
2025
Q4
$344K Hold
320
0.16% 58
2025
Q3
$244K Sell
320
-12
-4% -$8.93K 0.12% 66
2025
Q2
$259K Buy
332
+7
+2% +$5.44K 0.13% 58
2025
Q1
$269K Hold
325
0.14% 53
2024
Q4
$251K Hold
325
0.13% 56
2024
Q3
$288K Sell
325
-50
-13% -$45K 0.16% 47
2024
Q2
$340K Hold
375
0.21% 40
2024
Q1
$292K Sell
375
-25
-6% -$17.8K 0.19% 45
2023
Q4
$233K Hold
400
0.16% 48
2023
Q3
$215K Hold
400
0.19% 38
2023
Q2
$188K Buy
400
+25
+7% +$10.5K 0.16% 42
2023
Q1
$129K Hold
375
0.13% 52
2022
Q4
$137K Hold
375
0.14% 44
2022
Q3
$121K Hold
375
0.13% 47
2022
Q2
$122K Sell
375
-25
-6% -$7.5K 0.12% 51
2022
Q1
$115K Hold
400
0.1% 61
2021
Q4
$110K Buy
+400
New +$101K 0.08% 66

Other funds holding LLY

PFS Partners's LLY Position: Q2 2026 in Review

PFS Partners increased its Eli Lilly (LLY) stake by 0.31% in Q2 2026, buying an estimated $1.02K and bringing the position to 321 shares worth $384K. The position accounts for 0.16% of the portfolio, ranked #63.

PFS Partners first reported a position in LLY in Q4 2021 and has held it in 19 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • PFS Partners held 321 shares of Eli Lilly worth $384K as of Q2 2026.
  • PFS Partners bought 1 Eli Lilly share in Q2 2026, an estimated $1.02K.
  • Eli Lilly made up 0.16% of PFS Partners's portfolio in Q2 2026, its #63 holding.
  • PFS Partners first reported a position in Eli Lilly in Q4 2021 and has held it in 19 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on PFS Partners's 13F filing for Q2 2026, filed 20 Jul 2026.